Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$4.2 - $14.24 $571 - $1,936
-136 Reduced 99.27%
1 $0
Q3 2022

Nov 10, 2022

BUY
$9.85 - $16.83 $1,113 - $1,901
113 Added 470.83%
137 $2,000
Q2 2022

Aug 12, 2022

BUY
$8.16 - $15.1 $195 - $362
24 New
24 $0

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $236M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.